[ref. o42633102] Financial Accountant
Job description:
We pride ourselves on our integrity. We do what is right for our employees, patients, and partners, and so can you.
We are currently recruiting for a Financial Accountant to join the Finance team. The Financial Accountant plays a central role within finance, with responsibility for the UK Development Revenue, Cost of Sales and Group reporting support.
Our Finance team provide financial reporting, control, and accountancy across the business.
Your responsibilities in this role would be:
- Maintaining the UK revenue entries to ensure revenue recognition is accurate and in line with IFRS 15
- Reviewing the UK Cost of Sales entries and Project Margin reviews supporting the team to ensure that correct project cost allocations, including timesheets are being made and supporting revenue recognition
- Taking responsibility for maintaining relationships with stakeholders across the business to account for and reporting the development revenues generated by the UK site
- Ensuring a good understanding of our ERP system and related processes to take the role of ERP expert within the Finance Team
- Completing reporting analysis and commentary to explain variances within the finance team for reporting out to the business
- Participating with the wider team in the preparation of documentation for the year end audit
We are looking for:
- Qualified accountant or finalist
- Proven experience as a qualified accountant working within finance or an accounting practice
- Good Microsoft Office skills with advanced skills in MS Excel
- Strong technical experience with IFRS 15
- Good understanding of financial reporting and processes in a business environment
- Good knowledge and experience of ERP systems processes and transactions
- Strong communicator with the ability to build relationships cross functionally
- Ability to adapt to change in an agile way
About Us:
OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation.These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.
What’s in it for you:
- Highly competitive total reward packages
- Wellbeing programmes
- Development opportunities
- Welcoming, friendly, supportive colleagues
- A diverse and inclusive working environment
- Our values are: Responsible, Responsive, Resilient, Respect
- State of the art laboratory and manufacturing facilities
We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you.
Collaborate. Contribute. Change lives
We offer:
Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.
Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells.This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).
Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.